Sells vaccines and treatments for public-health threats to government customers, and naloxone nasal sprays to pharmacies, public agencies and community groups.
10-K for FY2025, filed Feb 27, 2026As of December 31, 2025, the Company has a portfolio of 11 products focused on addressing global public health threats like smallpox, mpox…View ↗
In the U.S. and Canadian markets, our Commercial business primarily focuses on sales of naloxone products, NARCAN® (naloxone HCl) Nasal…View ↗
Our Government - MCM business focuses primarily on procurement of MCM products and procured product candidates by domestic and…View ↗
Government buyers purchase MCM products through contracts, with sales tied to delivery and customer acceptance; pharmacies and wholesalers receive naloxone products. Bioservices customers pay as manufacturing and development work progresses, while reserved capacity is paid over time; contracts and grants also contribute.
10-K for FY2025, filed Feb 27, 2026The Company's contracts for the sale of the Company's Government - MCM products include certain acceptance criteria before title passes to…View ↗
The Company's OTC NARCAN® customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and…View ↗
Drug substance, drug product manufacturing, development services and technology transfer performance obligations are recognized as revenue…View ↗
Suite reservations are classified as leases when the customer directs the use of the identified suite and obtains substantially all the…View ↗
Our revenues are derived from a combination of the sale and procurement of our product/product candidate portfolio (described below), the…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$742.9M
10-K for FY2025, filed Feb 27, 2026
$742.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Commercial Product sales
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
30%
FY2022: 35%
|
Commercial Product sales, FY2025
$226.1M Sources
|
Sold outright |
|
MCM Product sales
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
61%
FY2022: 52%
|
MCM Product sales, FY2025
$456.7M Sources
|
Sold outright |
|
All other revenues
|
8.1% |
All other revenues, FY2025
$60.1M Sources
|
U.S. and other governments buy MCM products; naloxone is sold through pharmacies and online, and through prescriptions or standing orders to public agencies and community groups. Bioservices serve government agencies, pharmaceutical companies and nonprofits.
10-K for FY2025, filed Feb 27, 2026Our Government - MCM business focuses primarily on procurement of MCM products and procured product candidates by domestic and…View ↗
In the U.S. and Canadian markets, our Commercial business primarily focuses on sales of naloxone products, NARCAN® (naloxone HCl) Nasal…View ↗
The Company's Nasal Naloxone Products are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as…View ↗
Our services business consists of distinct but interrelated bioservices based on our manufacturing capabilities: drug substance…View ↗
10-K for FY2025, filed Feb 27, 2026
The Company’s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 46%, 39%…View ↗
Yes. It kept 7 cents of every revenue dollar as net income in FY2025 and turned 21 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$32.7MView ↗
10-Q for Q3 FY2026, filed Nov 3, 2026
Open tableView ↗
8-K, filed Apr 30, 2026
“Emergent’s first quarter results demonstrate a strong and positive start to 2026, with healthy topline revenue of $156 million, above the…View ↗
Shrinking. Revenue fell 58% in 4 years, from $1.8B in FY2021 to $742.9M in FY2025, about 20% a year.
Travel health divestiture
The older report included travelers’ vaccines sold through travel clinics, pharmacies and vaccination centers. The latest report focuses the commercial business on naloxone sprays and says the travel-health business was sold.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 27, 2026
Reduced services focus
The older report described development and manufacturing services for biotechnology and pharmaceutical innovators. The latest report says it reduced investment in and de-emphasized Services after facility closures and sales.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 27, 2026Our portfolio of CDMO services consists of three distinct but interrelated service pillars: development services (process and analytical…View ↗
Competes with KM Biologics, GC Biopharma, Blue Willow Biologics, Greffex, SIGA, Teva Pharmaceuticals Industries, Padagis Pharmaceuticals, Amneal Pharmaceuticals, Amphastar Pharmaceuticals, Adamis, Harm Reduction Therapeutics, Indivior, Summit Biosciences, Elusys Therapeutics, Thermo Fisher Scientific, Lonza, FUJIFILM Biotechnologies, Grand River Aseptic Manufacturing, Pyramid Bioservices, and PCI
10-K for FY2025, filed Feb 27, 2026ACAM2000®. ACAM2000® vaccine, which is licensed by the FDA for smallpox and mpox, and is licensed in Australia, Canada and Singapore for…View ↗
Loading...